NCT06710873进行中（未招募）不适用
Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年12月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- CIED infection
研究概览
简要总结
This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.
详细描述
This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients who received the TYRX absorbable antimicrobial envelopes at our hospital from December 2023 to September 2024
排除标准
- •Allergies to the envelope materials or antimicrobial drugs (minocycline and other tetracyclines, rifampin)
- •Existing infections at the CIED implantation site
- •Pregnant or breastfeeding women
- •children and adolescents
结局指标
主要结局
CIED infection
时间窗: three months post-surgery
The infection rate related to CIEDs at three months post-surgery
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaMelanomaNCT02447939GlaxoSmithKline
撤回
1 期
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid TumoursCancerNCT02939846GlaxoSmithKline
已完成
不适用
Evaluation of the TECNIS Symfony® Toric Intraocular LensCataractsNCT05053399Johnson & Johnson Surgical Vision, Inc.82
已完成
1 期
Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy VolunteersHealthy VolunteersNCT04213196Sichuan Haisco Pharmaceutical Group Co., Ltd66
Unknown
1 期
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy SubjectsT2DM (Type 2 Diabetes Mellitus)NCT05369078Newsoara Biopharma Co., Ltd.16